Main recent clinical trials in pulmonary arterial hypertension with either negative result or tolerability/safety issues

Study/compound(s)PhaseEnd-point: resultFormal presentation [ref.]Published [ref.]
ASA-STAT: aspirin and simvastatin26MWD: lack of efficacyYesYes [103]
ARROW: selonsertib (ASK-1 inhibitor)26MWD: lack of efficacyYes [62]No
Cicletanine (antihypertensive with vasorelaxant and diuretic properties)2PVR: lack of efficacyYes [104]No
Aviptadil (vasoactive intestinal peptide)2PVR: lack of efficacyYes [105]No
IMPRES: imatinib (tyrosine kinase inhibitor)36MWD: positive tolerability and safety issuesYesYes [45]
Terguride (partial dopamine agonist and serotonin receptor antagonist)26MWD: lack of efficacyYes [68]No
LIBERTY: ubenimex (leukotriene B4 inhibitor)2PVR: lack of efficacyNoNo

6MWD: 6-min walk distance; ASK1: apoptosis signal-regulating kinase 1; PVR: pulmonary vascular resistance.